Glycoengineering of αGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope

Glycobiology

Volumn 17, Issue 6, 2007, Pages 620-630

  Sadoulet, Marie Odile ^a,b,c   Franceschi, Cécile ^a,b,c   Aubert, Muriel ^d,e   Silvy, Françoise ^a,b,c   Bernard, Jean Paul ^a,b,c   Lombardo, Dominique ^a,b,c   Mas, Eric ^a,b,c  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Canceropole PACA   (France)

^d Cancer Research   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Antigen; Cancer; Glycotope; Pancreas; Tumor associated carbohydrate; 1,3 galactosyltransferase; Gal epitope

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA 1,3 GALACTOSYLTRANSFERASE ANTIBODY; ALPHA GALACTOSIDASE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; COMPLEMENTARY DNA; ENZYME ANTIBODY; EPITOPE; FETOACINAR PANCREAS PROTEIN; GLYCOTOPE J28; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J28; OLIGOSACCHARIDE; RECOMBINANT ALPHA 1,3 GALACTOSYLTRANSFERASE; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; GALACTOSYLTRANSFERASE; GLYCOPROTEIN; HETEROPHILE ANTIGEN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CLONE; CHEMICAL MODIFICATION; CHO CELL; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; ADENOCARCINOMA; ANIMAL; CHEMISTRY; CRICETULUS; ENZYMOLOGY; GENETICS; HAMSTER; IMMUNOLOGY; PANCREAS TUMOR;

CRICETULUS GRISEUS;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, HETEROPHILE; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CHO CELLS; CLONE CELLS; CRICETINAE; CRICETULUS; DNA, COMPLEMENTARY; EPITOPES; GALACTOSYLTRANSFERASES; GLYCOPROTEINS; HUMANS; PANCREATIC NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 34447321050     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwm028     Document Type: Article

References (54)

1. Abbruzzese JL. 2002. Past and present treatment of pancreatic adenocarcinoma: Chemiotherapy as a standard treatment modality. Semin Oncol. 29:2-8.
2. Abouakil N, Rogalska E, Bonicel J, Lombardo D. 1988. Purification of pancreatic carboxylic ester hydrolase by immunoaffinity and its application to the human bile salt-stimulated lipase. Biochim Biophys Acta. 961: 299-308.
3. Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E. 2003. Decrease of human pancreatic cancer cells tumorigenicity by α1,3galactosyltransferase gene transfer. Int J Cancer. 107:910-918.
4. Benedi VJ, Escribano MJ, Zuinghedau J, Burtin P. 1984. Fetal pancreatic antigens in the Syrian golden hamster and their relationship to the development and carcinogenesis. Cancer Res. 44:1135-1141.
5. Bierhuizen MF, Fukuda M. 1992. Expression cloning of a cDNA encoding UDP-GlcNAc:GAl beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc Natl Acad Sci USA. 89:9326-9330.
6. Bierhuizen MF, Maemura K, Fukuda M. 1994. Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase. J Biol Chem. 69:4473-4479.
7. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO. 2000. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res. 6:874-879.
8. Chen ZC, Tanemura M, Galili U. 2001. Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. Glycobiology. 11:577-586.
9. Collins BH, Cotterell AH, McCurry KR, Alvarado CG, Magee JC, Parker W, Platt JL. 1995. Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol. 154:5500-5510.
10. Cooper DK, Good AH, Koren E, Oriol R, Malcolm AJ, Ippolito RM, Neethling FA, Ye Y, Romano E, Zuhdi N. 1993. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transpl Immunol. 1:198-205.
11. Corzana F, Bettler E, Herve du Penhoat C, Tyrtysh TV, Bovin NV, Imberty A. 2002. Solution structure of two xenoantigens: Alpha Gal-LacNAc and alpha Gal-Lewis X. Glycobiology. 12:241-250.
12. Deriy L, Chen ZC, Gao GP, Galili U. 2002. Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. Glycobiology. 12:135-144.
13. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, et al. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 21:414-421.
14. Escribano MJ, Cordier J, Nap M, Ten Kate FJW, Burtin P. 1986. Differentiation antigens in fetal human pancreas. Reexpression in cancer. Int J Cancer. 38:155-160.
15. Escribano MJ, Imperial S. 1989. Purification and molecular characterization of FAP, a feto-acinar protein associated with the differentiation of human pancreas. J Biol Chem. 264:21865-21871.
16. Galili U. 2004. Autologous tumor vaccines processed to express alpha-gal epitopes: A practical approach to immunotherapy in cancer. Cancer Immunol Immunother. 53:935-945.
17. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. 1987. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc Natl Acad Sci USA. 84:1369-1373.
18. Galili U, Macher BA, Buehler J, Shohet SB. 1985. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)linked galactose residues. J Exp Med. 162:573-582.
19. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. 1988. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 56:1730-1737.
20. Galili U, Rachmilewitz EA, Peleg A, Flechner I. 1984. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 160:1519-1531.
21. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. 1988. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 263: 17755-17762.
22. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bommann WG, Spassova M, Bencsath KP, Panageas KS, et al. 2001. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial. Proc Natl Acad Sci USA. 98:3270-3275.
23. Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR. 1992. Identification of carbohydrate structures that bind human antiporcine antibodies: Implications for discordant xenografting in humans. Transplant Proc. 24:559-562.
24. Hakomori SI. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:5309-5318.
25. Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. 1991. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology. 100:1691-1700.
26. Jäger U, Takeuchi Y, Porter CD. 1999. Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer. Gene Therapy. 6:1073-1083.
27. Joziasse DH, Oriol R. 1999. Xenotransplantation: The importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta. 1455:403-418.
28. Kim S, Miura Y, Etchison JR, Freeze HH. 2001. Intact Golgi synthesize complex branched O-linked chains on glycoside primers: Evidence for the functional continuity of seven glycosyltransferases and three sugar nucleotide transporters. Glycoconj J. 18:623-633.
29. Kim YS, Itzkowitz SH, Yuan M, Chung Y, Satake K, Umeyama K, Hakomori S. 1988. Lex and Ley antigen expression in human pancreatic cancer. Cancer Res. 48:475-482.
30. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, et al. 2004. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res. 10:6094-6100.
31. LaTemple DC, Abrams JT, Zhang SY, Galili U. 1999. Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res. 59:3417-3423.
32. Liu J, Gustafsson A, Breimer ME, Kussak A, Holgersson J. 2005. Anti-pig antibody adsorption efficacy of α-Gal carrying recombinant P-selectin glycoprotein ligand-1/immunoglobulin chimeras increases with core 2 β1:6-N-acetylglucosaminyltransferase expression. Glycobiology. 15:571-583.
33. Lombardo D, Guy O. 1980. Studies on the subtrate specificity of a carboxyl ester hydrolase from human pancreatic juice. II Action on cholesterol esters and lipid-soluble vitamin esters. Biochim Biophys Acta. 611: 147-155.
34. Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D, Leclerc C. 2001. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol. 166:2849-2854.
35. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C. 2004. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64:4987-4994.
36. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. 1996. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol. 19:59-68.
37. Mas E, Abouakil N, Roudani S, Miralles F, Guy-Crotte O, Figarella C, Escribano MJ, Lombardo D. 1993. Human fetoacinar pancreatic protein: An oncofetal glycoform of the normally secreted pancreatic bile salt-dependent lipase. Biochem J. 289:609-615.
38. Mas E, Crotte C, Lecestre D, Michalski JC, Escribano MJ, Lombardo D, Sadoulet MO. 1997. The oncofetal J28 epitope involves fucosylated O-linked oligosaccharide structures of the fetoacinar pancreatic protein. Glycobiology. 7:745-752.
39. Mas E, Pasqualini E, Caillol N, El Battari A, Crotte C, Lombardo D, Sadoulet MO. 1998. The fucosyltransferase activities in human pancreatic tissues: Comparative study between cancer tissues and established cell lines. Glycobiology. 8:605-613.
40. Mazo A, Fujii Y, Shimotake J, Escribano MJ. 1991. Expression of fetoacinar pancreatic (FAP) protein in the pancreatic human tumor cell line BxPC-3. Pancreas. 6:37-45.
41. Miralles F, Limp F, Mazo A, Escribano MJ. 1993. Retention of the fetoacinar pancreatic (FAP) protein to the endoplasmic reticulum of tumor cells. Eur J Cell Biol. 60:115-121.
42. Oriol R, Ye Y, Koren E, Cooper DK. 1993. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation. 56:1433-1442.
43. Panicot L, Mas E, Pasqualini E, Zerfaoui M, Lombardo D, Sadoulet MO, El Battari A. 1999. The formation of the oncofetal J28 epitope involves core-2 β6-N-acetylglucosaminyl-transferase and α(1-3/4) fucosyltransferase activities. Glycobiology. 9:935-946.
44. Panicot L, Mas E, Thivolet C, Lombardo D. 1999. Circulating antibodies against an exocrine pancreatic enzyme in type 1 diabetes. Diabetes. 48: 2316-2323.
45. Panicot-Dubois L, Aubert M, Franceschi C, Mas E, Silvy F, Crotte C, Bernard JP, Lombardo D, Sadoulet MO. 2004. Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts. Neoplasia. 6:713-724.
46. Pasqualini E, Caillol N, Panicot L, Mas E, Lloubes R, Lombardo D. 1998. Molecular cloning of the oncofetal isoform of the human pancreatic bile salt-dependent lipase. J Biol Chem. 273:28208-28218.
47. Ræder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, Nermoen I, Eide SA, Grevle L, Bjørkhaag L, et al. 2006. Mutations in CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 38:54-62.
48. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. 2000. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer. 85:659-666.
49. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. 1999. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother. 22:54-66.
50. Slovin SF, Keding SJ, Ragupathi G. 2005. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol. 83:418-28.
51. Takeda Y, Miralles F, Daher N, Escribano MJ. 1992. Radioimmunolocalization of the monoclonal antibody J28 in early transformation stages in N-nitrosobis(2-hydroxypropyl)amine-induced pancreatic tumors in the Syrian golden hamster. J Cancer Res Clin Oncol. 118:377-385.
52. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO, Chu TM. 1986. Characterization of a new primary human pancreatic tumor line. Cancer Invest, 4:15-23.
53. Unfer RC, Hellrung D, Link CJ. 2003. Immunity to the α(1,3 galactosyl epitope provides protection in mice challenged with colon cancer cells expressing α(1,3) galactosyltransferase: A novel suicide gene for cancer gene therapy. Cancer Res. 63:987-993.
54. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 22:1393-1398.